DDM Holding AG (First North: DDM), a specialist investor in and manager of non -performing loans and distressed assets, announces that it has made significant loan repayments in excess of EUR 8M during the third quarter of 2016. The loan repayments include the full redemption of the SEK 31M 18% subordinated notes issued by DDM Treasury Sweden AB on their final maturity date of 30 September 2016. In addition, repayments of about EUR 3M were made on the EUR 11M bond issued in July 2016, following strong performance by the recently acquired Slovenian portfolio. Additionally, EUR 2M out of the EUR 4M of short-term borrowings granted in March 2016 were repaid during the quarter. The loan repayments were financed using cash on hand. These repayments have enabled DDM to reduce its gross debt by more than 15% compared to reported gross debt as per end of Q2 2016 and the new bond of EUR 11M raised in July. It also means a reduction in its cost of debt. Roschier acted as DDM’s legal advisors in conjunction with the redemption of the subordinated notes. This information is information which DDM Holding AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 a.m. CET on 3 October 2016. For more information, please visit DDM’s website at www.ddm-group.ch or contact: Gustav Hultgren, CEO Mail: investor@ddm-group.ch | Tel: 46 8 4080 9030 DDM Holding AG (Nasdaq First North Stockholm: DDM) is a key acquirer and manager of distressed assets. Since 2007, the DDM Group has built a successful platform in Eastern Europe, currently managing 2.3 million receivables with a nominal value of over EUR 2.1 billion. DDM Treasury Sweden AB (publ) (NGM: DDM1) is a subsidiary wholly owned by DDM Holding AG. Erik Penser Bank is DDM Holding AG’s Certified Adviser.
DDM makes significant loan repayments in excess of EUR 8M,
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Insights from the New First Presidency on Global Challenges
A Historic Conversation with the First Presidency The recent interview featuring the new First Presidency of The Church of Jesus Christ of Latter-day Saints marks an exciting milestone. Conducted by the talented Jane Clayson Johnson, this unique dialogue sheds light on pressing issues within the Church and broader society. It was their first public discussion, making it a...
Continue Reading
Major Bets on Donald Trump's Election Surge Past $52 Million
Significant Bets on Trump's Electoral Success A trader on Polymarket, operating under the alias Fredi9999, alongside four other accounts, has made headlines recently by placing enormous bets on Donald Trump’s electoral prospects. This activity has generated considerable chatter among traders in the market. Tracking Trump's Betting Activity Harry Crane, a statistics...
Continue Reading
FMC Corporation Faces Lawsuit Over Securities Violations
FMC Corporation Faces Lawsuit Over Securities Violations Recently, the Gross Law Firm has alerted shareholders of FMC Corporation (NYSE: FMC) regarding significant legal developments. This lawsuit brings attention to serious allegations concerning the company's conduct during a specific class period. Shareholder Engagement and Participation Shareholders who purchased FMC...
Continue Reading
Insider Buying at Optima Health Signals Confidence in Future Growth
Insightful Insider Share Purchase at Optima Health Optima Health plc (AIM: OPT), a leading provider of corporate health and wellbeing solutions in the UK, recently announced an important transaction involving one of its key insiders. Joanne Newey, who takes on the role of Group Business Development & Propositions Director and is also a Person Discharging Managerial...
Continue Reading
Outlook Therapeutics Prepares for Upcoming Investor Interaction
Outlook Therapeutics Connects with Investors at Upcoming Virtual Event ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) has been making waves in the biopharmaceutical field with its groundbreaking ocular therapy. This marks an exciting era for the company following the recent approval of its eye treatment formulation of bevacizumab, which targets wet age-related...
Continue Reading